DL-Aminoglutethimide is primarily used in the medical field for its ability to inhibit steroidogenesis, making it valuable in the treatment of certain hormone-dependent conditions. It is commonly employed in the management of Cushing's syndrome, a disorder caused by excessive cortisol production. By blocking the conversion of cholesterol to pregnenolone, it reduces the synthesis of cortisol, alleviating symptoms associated with the syndrome.

Additionally, it has been utilized in the treatment of advanced breast cancer, particularly in postmenopausal women. Its mechanism involves suppressing the production of estrogen, which can fuel the growth of hormone-sensitive tumors. This makes it a useful adjunct in hormone therapy for cancer patients.

In veterinary medicine, DL-Aminoglutethimide has also been explored for its potential to treat adrenal gland disorders in animals, particularly in cases of hyperadrenocorticism (Cushing's disease). Its ability to modulate steroid production makes it a versatile tool in both human and animal healthcare.